Clinical trial
Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to…
NCT00492258 · Medical Research Council, Other · Completed
Key facts
| NCT number | NCT00492258 |
|---|---|
| Title | Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer |
| Official title | SORCE: A Phase III Randomised Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse |
| Lead sponsor | Medical Research Council, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug, Procedure |
| Interventions | sorafenib tosylate, adjuvant therapy |
| Enrollment | 1,656 |
| Start date | Jun 1, 2007 |
| Primary completion | Aug 1, 2012 |
| Completion | Dec 1, 2012 |
| First posted | Jun 27, 2007 |
| Last update posted | Aug 12, 2013 |
| Countries | United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: